Drug Safety and Outcomes in Respiratory and Critical Care Medicine
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 1077
Special Issue Editor
Interests: respiratory medicine; pulmonology; intensive care medicine; drug safety; pharmacotherapy; clinical outcomes research; critical illness; evidence-based medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmacological therapies remain a cornerstone in the prevention, diagnosis, and management of respiratory diseases and in the treatment of critically ill patients. In clinical practice, physicians are often faced with the challenge of balancing therapeutic efficacy against the potential risk of adverse drug reactions, drug–drug interactions, and treatment-related complications. In respiratory and intensive care medicine, these challenges are amplified by the complexity of disease mechanisms, the heterogeneity of patient populations, and the frequent use of multiple concomitant medications.
The primary aim of this Special Issue is to provide a comprehensive overview of current evidence and emerging insights into drug safety and clinical outcomes in respiratory and critical care settings. We seek to highlight advances in pharmacological strategies, to identify risk factors associated with poor drug tolerance or therapeutic failure, and to explore innovative approaches to improve patient safety and optimize treatment results. Contributions that examine the mechanisms of drug toxicity, novel biomarkers for monitoring therapy, and strategies to prevent adverse events will be of particular interest.
We welcome original research articles, clinical trials, systematic reviews, meta-analyses, and state-of-the-art reviews. Submissions may address a broad range of topics, including but not limited to safety and effectiveness of established pharmacological interventions in respiratory diseases such as asthma, COPD, pneumonia, pulmonary hypertension, or interstitial lung diseases; pharmacotherapy in acute respiratory failure, sepsis, and multi-organ dysfunction; the impact of polypharmacy in intensive care settings; and translational research that bridges basic pharmacological science with clinical application. Studies involving real-world data, multicenter collaborations, and patient-centered outcome measures are strongly encouraged.
By bringing together high-quality contributions from both clinical and translational research, this Special Issue aims to advance knowledge in the field, foster interdisciplinary exchange, and provide clinicians and researchers with a solid foundation for evidence-based decision-making. Ultimately, our goal is to support safer and more effective drug use in respiratory and critical care medicine, thereby improving both short- and long-term outcomes for patients worldwide.
Dr. Josef Yayan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug safety
- adverse drug reactions
- pharmacovigilance
- critical care medicine
- respiratory diseases
- clinical outcomes
- intensive care pharmacotherapy
- drug–drug interactions
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
